Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109,455Revenue $M16,383Net Margin (%)10.9Altman Z-Score6.3
Enterprise Value $M111,517EPS $1.1Operating Margin %17.0Piotroski F-Score7
P/E(ttm)61.3Beneish M-Score-2.1Pre-tax Margin (%)14.9Higher ROA y-yN
Price/Book7.210-y EBITDA Growth Rate %-1.4Quick Ratio1.6Cash flow > EarningsY
Price/Sales6.75-y EBITDA Growth Rate %-14.3Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow69.6y-y EBITDA Growth Rate %-22.0ROA % (ttm)5.4Higher Current Ratio y-yN
Dividend Yield %2.2PEG--ROE % (ttm)11.8Less Shares Outstanding y-yY
Payout Ratio %138Shares Outstanding M1,668ROIC % (ttm)5.1Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYVanguard Health Care Fund 2015-06-30 Add0.11%$63 - $69.15
($65.88)
$ 65.64-0%Add 1.90%43,718,751
BMYKahn Brothers 2015-06-30 Add$63 - $69.15
($65.88)
$ 65.64-0%Add 1.41%28,800
BMYKen Fisher 2015-06-30 Add$63 - $69.15
($65.88)
$ 65.64-0%Add 6.77%34,636
BMYVanguard Health Care Fund 2015-03-31 Add0.53%$58.48 - $68.47
($62.6)
$ 65.645%Add 9.85%42,902,031
BMYBrian Rogers 2015-03-31 Reduce-0.09%$58.48 - $68.47
($62.6)
$ 65.645%Reduce 7.18%5,814,800
BMYRonald Muhlenkamp 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 65.645%Reduce 0.06%212,170
BMYMario Gabelli 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 65.645%Reduce 0.75%704,425
BMYDodge & Cox 2015-03-31 Reduce$58.48 - $68.47
($62.6)
$ 65.645%Reduce 3.52%87,828
BMYKen Fisher 2015-03-31 Add$58.48 - $68.47
($62.6)
$ 65.645%Add 5.54%32,441
BMYVanguard Health Care Fund 2014-12-31 Add0.08%$48.92 - $61.3
($56.49)
$ 65.6416%Add 1.50%39,056,361
BMYKahn Brothers 2014-12-31 Add0.01%$48.92 - $61.3
($56.49)
$ 65.6416%Add 2.71%28,400
BMYMario Gabelli 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 65.6416%Add 1.35%709,715
BMYKen Fisher 2014-12-31 Reduce$48.92 - $61.3
($56.42)
$ 65.6416%Reduce 39.96%30,739
BMYRonald Muhlenkamp 2014-12-31 Reduce$48.92 - $61.3
($56.49)
$ 65.6416%Reduce 0.09%212,290
BMYRuane Cunniff 2014-12-31 Buy $48.92 - $61.3
($56.53)
$ 65.6416%New holding3,670
BMYDodge & Cox 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 65.6416%Add 0.66%91,028
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 65.6431%Add 6.31%38,480,761
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 65.6431%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 65.6433%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 65.6433%New holding89,363
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Caldarella Joseph CSVP & Controller 2015-06-04Sell16,972$65.71-0.11view
Schmukler Louis SPres., Global Mfg. & Supply 2015-03-16Sell12,000$66.96-1.97view
Cuss Francis MEVP & CSO 2015-03-16Sell114,666$67.81-3.2view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-13Sell591$66.67-1.54view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-10Sell10,343$65.84-0.3view
Elicker John ESVP Pub Affairs & Inv Relation 2015-03-06Sell10,468$66.24-0.91view
LEUNG SANDRAGeneral Counsel & Secretary 2015-02-17Sell11,746$60.398.69view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-12Sell3,880$59.2610.77view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-06Sell21,478$60.159.13view
CORNELIUS JAMES MDirector 2015-01-30Sell50,000$60.68.32view

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
Will Bill Ackman Go After Express Scripts Next? Jun 30 2015 
Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
gild Jun 02 2015 
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
Piper Jaffray Sees Potential in uniQure NV (QURE) and Bristol-Myers Squibb (BMY) Collaboration Apr 07 2015 

More From Other Websites
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying... Jul 29 2015
BRISTOL MYERS SQUIBB CO Financials Jul 29 2015
Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers Jul 29 2015
Abbott Laboratories Earnings Analysis: By the Numbers Jul 29 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Gilead beats Street 2Q forecasts on surge in sales, profit Jul 28 2015
Drugmaker Pfizer tops Street 2Q forecasts, raises forecast Jul 28 2015
Drugmaker Pfizer tops Street 2Q forecasts, raises forecast Jul 28 2015
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo... Jul 28 2015
Short Sellers Run For Cover From Major Pharma Jul 27 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization... Jul 27 2015
European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization... Jul 27 2015
10-Q for Bristol-Myers Squibb Co. Jul 25 2015
Bristol-Myers wins approval for 1st hepatitis C type 3 drug Jul 24 2015
Bristol-Myers wins approval for 1st hepatitis C type 3 drug Jul 24 2015
UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments Jul 24 2015
FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype... Jul 24 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK